An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease
Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Despite the advent of newer biologic therapies such as infliximab for Crohn's disease, a form
of autoimmune inflammatory bowel disease, a proportion of patients are refractory to such
therapy and require surgery. The hypothesis is that mesenchymal stromal cell therapy using
third party human cultured cells will be safe and effective
Phase:
Phase 2
Details
Lead Sponsor:
R.P.Herrmann
Collaborators:
Concord Hospital Sir Charles Gairdner Hospital The Alfred The Queen Elizabeth Hospital